Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia

Annals of the New York Academy of Sciences

Volumn 1207, Issue , 2010, Pages 89-96

  Melani, Alessia ^a   Cipriani, Sara ^a   Corti, Francesca ^a   Pedata, Felicita ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Chronic ischemia; Cognition tests; Dipyridamole; Neurological deficit; Two vessel occlusion

Indexed keywords

DIPYRIDAMOLE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CHRONIC BRAIN DISEASE; CHRONIC BRAIN ISCHEMIA; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG EFFECT; NONHUMAN; RAT; SPATIAL MEMORY; TREATMENT OUTCOME; WORKING MEMORY; ANIMAL; DISEASE MODEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEMORY; PSYCHOLOGICAL ASPECT; REVIEW; STROKE;

RATTUS; RODENTIA;

ANIMALS; BRAIN ISCHEMIA; CAROTID ARTERY, COMMON; DIPYRIDAMOLE; DISEASE MODELS, ANIMAL; HUMANS; INFUSIONS, INTRAVENOUS; MEMORY; NEUROPROTECTIVE AGENTS; RATS; STROKE;

EID: 78149263840     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05732.x     Document Type: Article

References (78)

1. Chmayssani, M., J.R. Festa & R.S. Marshall. 2007. Chronic ischemia and neurocognition. Neuroimaging Clin. N. Am. 17: 313-324.
2. Naritomi, H. 1991. Experimental basis of multi-infarct dementia: memory impairments in rodent models of ischemia. Alzheimer Dis. Assoc. Disord. 5: 103-111.
3. Ohtaki, H. et al. 2006. Progressive expression of vascular endothelial growth factor (VEGF) and angiogenesis after chronic ischemic hypoperfusion in rat. Acta Neurochir. Suppl. 96: 283-287.
4. Ozacmak,VH.et al. 2007.AT1 receptor blocker candesartaninduced attenuation of brain injury of rats subjected to chronic cerebral hypoperfusion. Neurochem. Res. 32: 1314- 1321.
5. Sarti, C. et al. 2002a. Cognitive impairment and chronic cerebral hypoperfusion: what can be learned from experimental models. J. Neurol. Sci. 203-204: 263-266.
6. de la Torre, J.C. & T. Fortin. 1994. A chronic physiological rat model of dementia. Behav. Brain Res. 63: 35-40.
7. de la Torre, J.C. et al. 1992. Chronic cerebrovascular insufficiency induces dementia-like deficits in aged rats. Brain Res. 582: 186-195.
8. Kudo, T. et al. 1990. Learning impairment andmicrotubuleassociated protein 2 decrease in gerbils under chronic cerebral hypoperfusion. Stroke 21: 1205-1209.
9. Ni, J. et al. 1994. Progressive cognitive impairment following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries in rats. Brain Res. 653: 231-236.
10. Ohta, H. et al. 1997. Chronic cerebral hypoperfusion by permanent internal carotid ligation produces learning impairment without brain damage in rats. Neuroscience 79: 1039-1050.
11. Pappas, B.A. et al. 1996. Chronic reduction of cerebral blood flowin the adult rat: late-emergingCA1cell loss andmemory dysfunction. Brain Res. 708: 50-58.
12. Sarti, C. et al. 2002b. Persistent impairment of gait performances andworkingmemory after bilateral commoncarotid artery occlusion inthe adultWistar rat. Behav.BrainRes. 136: 13-20.
13. Cho, K.O. et al. 2006. Minocycline attenuates white matter damage in a rat model of chronic cerebral hypoperfusion. J. Neurosci. Res. 83: 285-291.
14. Wakita, H. et al. 2003. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Res. 992: 53-59.
15. Farkas, E., P.G. Luiten & F. Bari. 2007. Permanent, bilateral common carotid artery occlusion in the rat: a model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res. Rev. 54: 162-180.
16. Liu, C. et al. 2007. Baicalein improves cognitive deficits induced by chronic cerebral hypoperfusion in rats. Pharmacol. Biochem. Behav. 86: 423-430.
17. Takizawa, S. et al. 2003. Reperfusion enhances nitrotyrosine formation in rat focal cerebral ischemia. J. Stroke Cerebrovasc. Dis. 12: 196-200.
18. Gold, G. et al. 2005. Cognitive consequences of thalamic, basal ganglia, and deep white matter lacunes in brain aging and dementia. Stroke 36: 1184-1188.
19. Mracskó, E. et al. 2010. Changes in pro-oxidant and antioxidant enzyme levels during cerebral hypoperfusion in rats. Brain Res. 1321: 13-19.
20. Cai, Z.Y., Y. Yan&R. Chen. 2010.Minocycline reduces astrocytic reactivation and neuroinflammation in the hippocampus of a vascular cognitive impairment rat model. Neurosci. Bull. 26: 28-36.
21. Wang, J., H.Y. Zhang & X.C. Tang. 2010. Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. J. Neurosci. Res. 88: 807- 815.
22. Farkas, E. et al. 2005. Diazoxide and dimethyl sulphoxide alleviate experimental cerebral hypoperfusion-induced white matter injury in the rat brain. Neurosci. Lett. 373: 195-199.
23. Vicente, E. et al. 2009. Astroglial and cognitive effects of chronic cerebral hypoperfusion in the rat. Brain Res. 1251: 204-212.
24. Watanabe, T. et al. 2006. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke 37: 1539- 1545.
25. Ji,H.J. et al. 2010. Osthole improves chronic cerebral hypoperfusion induced cognitive deficits and neuronal damage in hippocampus. Eur. J. Pharmacol. 636: 96-101.
26. Figueredo, V.M. et al. 1999. Chronic dipyridamole therapy produces sustained protection against cardiac ischemiareperfusion injury. Am. J. Physiol. 277: H2091-H2097.
27. Riksen,N.P. et al. 2005. Oral therapywith dipyridamole limits ischemia-reperfusion injury in humans. Clin. Pharmacol. Ther. 78: 52-59.
28. Henrichs, K.J., H. Matsuoka & W. Schaper. 1983. Mode of action of adenosine-potentiating vasodilators. In: Regulatory Function of Adenosine. R.M. Berne, T.W. Frall & R. Rubio, Eds.: 517-523. Nijhoff. Boston.
29. Phillis, J.W. 2004. Adenosine and adenine nucleotides as regulators of cerebral blood flow: roles of acidosis, cell swelling, and KATP channels. Crit. Rev. Neurobiol. 16: 237-270.
30. Kusano, Y. et al. 2010. Role of adenosine A2 receptors in regulation of cerebral blood flow during induced hypotension. J. Cereb. Blood Flow Metab. 30: 808-815.
31. Born, G.V.R. & M.J. Cross. 1963. Inhibition of the aggregation of blood platelets by substances related to adenosine diphosphate. J. Physiol. 166: 29P-30P.
32. Heptinstall, S. et al. 1986. Inhibition of platelet aggregation in whole blood by dipyridamole and aspirin. Thromb. Res. 42: 215-223.
33. Elkeles, R.S. et al. 1968. Effect of a pyrimido-pyrimidine compound on platelet behaviour in vitro and in vivo. Lancet. 2: 751-754.
34. Olsson, J.E. et al. 1980. Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke 11: 4-9.
35. Bousser, M.G. et al. 1983. " AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 14: 5-14.
36. American-Canadian Co-Operative Study Group. 1985. Persantine aspirin trial in cerebral ischemia. Part II: Endpoint results. Stroke 16: 406-415.
37. The ESPRIT Study Group. 2006. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367: 1665- 1673.
38. Forbes, C.D. 1997. European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Int. J. Clin. Pract. 51: 205-208.
39. Chairangsarit, P. et al. 2005. Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. J. Med. Assoc. Thai. 88: S148-S154.
40. Diener, H.C. 2006. How much esprit is in ESPRIT? Stroke 37: 2856-2857.
41. Sacco, R.L. et al. 2006. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 113: e409-e449.
42. Aktas, B. et al. 2003. Dipyridamole enhances NO/cGMPmediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 34: 764-769.
43. Eisert, W. 2002. Dipyridamole. In Platelets. A. Michelson, Ed.: 803-815. Academic Press. London.
44. Blake, A.D. 2004. Dipyridamole is neuroprotective for cultured rat embryonic cortical neurons. Biochem. Biophys. Res. Commun. 314: 501-504.
45. Iuliano, L. et al. 1995. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic. Biol. Med. 18: 239-247.
46. Vargas, F. et al. 2003.Antioxidant properties of dipyridamole as assessed by chemiluminescence. Pharmazie 58: 817-823.
47. Al-Bahrani, A. et al. 2007. TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. Curr. Neurovasc. Res. 4: 31-37.
48. Weyrich, A.S. et al. 2005. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 111: 633-642.
49. Chen, T.H. et al. 2006. Dipyridamole activation of mitogenactivated protein kinase phosphatase-1 mediates inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264.7 cells. Eur. J. Pharmacol. 541: 138-146.
50. Schilling, M. et al. 2009. Effects of monocyte chemoattractant protein 1 on blood-borne cell recruitment after transient focal cerebral ischemia in mice. Neuroscience 161: 806-812.
51. Hughes, P.M. et al. 2002. Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J. Cereb. Blood Flow Metab. 22: 308-317.
52. Dimitrijevic, O.B. et al. 2007. Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. Stroke 38: 1345-1353.
53. Chakrabarti, S. & J.E. Freedmans 2008. Dipyridamole, cerebrovascular disease, and the vasculature. Vascul. Pharmacol. 48: 143-149.
54. Venkatesh, P.K. et al. 2010. Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/ nitric oxide-dependent pathway. Cardiovasc. Res. 85: 661-670.
55. Ernens, I. et al. 2010. Adenosine up-regulates vascular endothelial growth factor in human macrophages. Biochem. Biophys. Res. Commun. 392: 351-356.
56. Hsieh, M.S. et al. 2010. Dipyridamole suppresses high glucose-induced osteopontin secretion and mRNA expression in rat aortic smooth muscle cells. Circ. J. 74: 1242- 1250.
57. Chello, M. et al. 1999. Inhibition by dipyridamole of neutrophil adhesion to vascular endothelium during coronary bypass surgery. Ann. Thorac. Surg. 67: 1277-1282.
58. Newell, D.R. et al. 1986. The effect of the nucleoside transport inhibitor dipyridamole on the incorporation of [3H]thymidine in the rat. Biochem. Pharmacol. 35: 3871- 3877.
59. Serebruany, V. et al. 2009. Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation. Thromb. Haemost. 102: 538- 543.
60. Jones, L.F., S.K. Landas & A.K. Johnson. 1994.Measurement of coronary blood flow velocity in conscious rats. Am. J. Physiol. 266: H840-H845.
61. Hung, K.Y. et al. 2001. Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. Kidney Int. 59: 2316-2324.
62. Ritchie, L.J.,M. De Butte & B.A. Pappas. 2004. Chronic mild stress exacerbates the effects of permanent bilateral common carotid artery occlusion on CA1 neurons. Brain Res. 1014: 228-235.
63. Kim, D.H. et al. 2006. Effect of the flavonoid, oroxylin A, on transient cerebral hypoperfusion-induced memory impairment in mice. Pharmacol. Biochem. Behav. 85: 658-668.
64. Annaházi, A. et al. 2007. Pre-treatment and post-treatment with alpha-tocopherol attenuates hippocampal neuronal damage in experimental cerebral hypoperfusion. Eur. J. Pharmacol. 571: 120-128.
65. Xu, L., Q. Di & Y. Zhang. 2008. Cell cycle proteins preceded neuronal death after chronic cerebral hypoperfusion in rats. Neurol. Res. 30: 932-939.
66. Tomimoto, H. et al. 2003. Chronic cerebral hypoperfusion induces white matter lesions and loss of oligodendroglia with DNA fragmentation in the rat. Acta Neuropathol. 106: 527-534
67. Lee, H. et al. 2009. Doxycycline inhibits matrix metalloproteinase-9 and laminin degradation after transient global cerebral ischemia. Neurobiol. Dis. 34: 189-198.
68. Odano, I. et al. 1995. A potential use of a 123I-labelled benzodiazepine receptor antagonist as a predictor of neuronal cell viability: comparisonswith 14C-labelled 2-deoxyglucose autoradiography and histopathological examination. Nucl. Med. Commun. 16: 443-446.
69. Garcia, J.H. et al. 1995. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 26: 627-634.
70. Pedata, F. et al. 2005. The protective effect of adenosine A2A receptor antagonism in cerebral ischemia. Neurol. Res. 27: 169-174.
71. Aronowski, J., R. Strong & J.C. Grotta. 1996. Citicoline for treatment of experimental focal ischemia: histologic and behavioral outcome. Neurol. Res. 18: 570-574.
72. Plaschke, K. et al. 1999. Interrelation between cerebral energy metabolism and behaviour in a rat model of permanent brain vessel occlusion. Brain Res. 830: 320-329.
73. Weinstock, M. & S. Shoham. 2004. Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity. J. Neural. Transm. 111: 347-366.
74. Green, A.R. 2002.Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective. Clin. Exp. Pharmacol. Physiol. 29: 1030-1034.
75. Yamaguchi, T., M. Suzuki & M. Yamamoto. 1995. YM796, a novel muscarinic agonist, improves the impairment of learning behavior in a rat model of chronic focal cerebral ischemia. Brain Res. 669: 107-114.
76. Kawamata, T. et al. 1996. Intracisternal basic fibroblast growth factor (bFGF) enhances behavioral recovery following focal cerebral infarction in the rat. J. Cereb. Blood Flow Metab. 16: 542-547.
77. Roof, R.L. et al. 2001. A comparison of long-termfunctional outcome after 2 middle cerebral artery occlusion models in rats. Stroke 32: 2648-2657.
78. Durukan A. & T. Tatlisumak. 2007. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol. Biochem. Behav. 87: 179-197.